Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Mylan Gains License to Gilead HIV/AIDS Products 
 | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Mylan Gains License to Gilead HIV/AIDS Products 


Mylan's Matrix Laboratories Ltd. entered an expanded licensing agreement with Gilead Sciences for the rights to produce and market generic versions of three Gilead HIV/AIDS therapies, currently in late-stage development.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Mylan’s Matrix Laboratories Ltd. entered an expanded licensing agreement with Gilead Sciences for the rights to produce and market generic versions of three Gilead HIV/AIDS therapies, currently in late-stage development. They include: Elvitegravir, an investigational integrase inhibitor, Cobicistat, an investigational antiretroviral (ARV) boosting agent, and the “Quad,” a once-daily, single-tablet combination of four separate Gilead medicines.

Mylan President Heather Bresch said: “Every patient living with HIV/AIDS has a right to treatment. Matrix has made a significant contribution to dramatically lowering the cost of HIV/AIDS medicines, and we are now focused on expanding access to high-quality treatment to more people who need it. We are pleased to expand our collaboration with Gilead as it will enable more individuals living with HIV/AIDS in resource-limited countries to access the newest innovative medicines.”
   
Under previous licensing agreements Matrix obtained non-exclusive rights to produce and market APIs and finished products, including generic versions of Viread and other TDF-based combinations in 95 developing countries including India. The expanded agreement allows for the sale of Viread, Truvada and other TDF-based combinations in 16 additional countries and for the production and sale of Viread as a treatment for chronic hepatitis B in an expanded territory.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics